Pregnancy & Lactation : הריון/הנקה

4.6      Fertility, pregnancy and lactation
Pregnancy
There are no adequate data from the use of gemcitabine in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Based on results from animal studies and the mechanism of action of gemcitabine, this substance should not be used during pregnancy unless clearly necessary. Women should be advised not to become pregnant during treatment with gemcitabine and to warn their attending physician immediately, should this occur after all.


Gemcitabine Teva Concentrate for Solution for Infusion, KL05/2024
Breast-feeding
It is unknown whether gemcitabine is excreted in human milk, and adverse effects on the suckling child cannot be excluded. Breast-feeding must be discontinued during Gemcitabine therapy.

Fertility
In fertility studies gemcitabine caused hypospermatogenesis in male mice (see section 5.3).
Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine.